Leading pharmaceutical companies and total global vaccine market share 2017 and 2024

Top 10 pharmaceutical companies based on global vaccine revenue market share in 2017 and 2024

by Matej Mikulic, last edited Jun 19, 2019
Leading pharmaceutical companies and total global vaccine market share 2017 and 2024 The top ten pharmaceutical companies based on global vaccine revenue market share in 2017 and a projection for 2024 include companies like GlaxoSmithKline and CSL. In 2017, GlaxoSmithKline (GSK) was the top pharmaceutical company and held about 24 percent of the global vaccine market by revenue. GSK is expected to maintain their position as the top company and even gain a small amount of the market until 2024. Pfizer is expected to account for some 16 percent of the global vaccine market by 2024, largely due to success with its pneumococcal vaccine, Prevnar 13. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.
Vaccinations market globally

The vaccination market, while important to global health, is relatively smaller than other pharmaceuticals. The vaccination market is heavily regulated globally and depends heavily on the policies of donors and public purchasers. The total global vaccination market has been growing and expected to continue to grow. Current and projected estimates indicate that North America holds the largest proportion of the market, followed by Europe.

Vaccination spotlight: pneumococcal disease

There are various vaccines for many kinds of diseases. In 2017, the top vaccine product based on revenue was Prevnar 13 which is marketed by Pfizer and Daewoong. Prevnar is a vaccination for the prevention of invasive disease caused by certain streptococcus pneumoniae serotypes. In the U.S., the vaccination coverage for pneumococcal disease among adults aged 65 and older is almost as high as the vaccination rate for influenza. Pneumonia, for example, is a serious health problem and represents one of the top leading causes of death in the United States.
Show more

Top 10 pharmaceutical companies based on global vaccine revenue market share in 2017 and 2024

Loading statistic...
Expand statistic
20172024*
GlaxoSmithKline24%24.1%
Merck & Co.23.6%21.1%
Sanofi20.8%18.2%
Pfizer21.7%16.3%
Novavax-5.9%
Emergent BioSolutions1%2.5%
CSL3%2.4%
Inovio Pharmaceuticals-1.5%
Bavarian Nordic0%1.2%
Mitsubishi Tanabe1.5%1.1%
20172024*
GlaxoSmithKline24%24.1%
Merck & Co.23.6%21.1%
Sanofi20.8%18.2%
Pfizer21.7%16.3%
Novavax-5.9%
Emergent BioSolutions1%2.5%
CSL3%2.4%
Inovio Pharmaceuticals-1.5%
Bavarian Nordic0%1.2%
Mitsubishi Tanabe1.5%1.1%
Download Settings Share
Download started
Please be patient - this may take a moment
by Matej Mikulic, last edited Jun 19, 2019
The top ten pharmaceutical companies based on global vaccine revenue market share in 2017 and a projection for 2024 include companies like GlaxoSmithKline and CSL. In 2017, GlaxoSmithKline (GSK) was the top pharmaceutical company and held about 24 percent of the global vaccine market by revenue. GSK is expected to maintain their position as the top company and even gain a small amount of the market until 2024. Pfizer is expected to account for some 16 percent of the global vaccine market by 2024, largely due to success with its pneumococcal vaccine, Prevnar 13. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.
Vaccinations market globally

The vaccination market, while important to global health, is relatively smaller than other pharmaceuticals. The vaccination market is heavily regulated globally and depends heavily on the policies of donors and public purchasers. The total global vaccination market has been growing and expected to continue to grow. Current and projected estimates indicate that North America holds the largest proportion of the market, followed by Europe.

Vaccination spotlight: pneumococcal disease

There are various vaccines for many kinds of diseases. In 2017, the top vaccine product based on revenue was Prevnar 13 which is marketed by Pfizer and Daewoong. Prevnar is a vaccination for the prevention of invasive disease caused by certain streptococcus pneumoniae serotypes. In the U.S., the vaccination coverage for pneumococcal disease among adults aged 65 and older is almost as high as the vaccination rate for influenza. Pneumonia, for example, is a serious health problem and represents one of the top leading causes of death in the United States.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Merck & Co.
Merck & Co.

All Information
in one Presentation

Merck & Co.

Everything On "Merck & Co." in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Merck & Co."
  • Global positioning
The most important statistics
  • Overview
  • Revenues
  • Expenses
  • Shares/stockholders
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.